Quick Answer
Fortress Biotech, Inc. reported Total Revenue of $63.26 million for fiscal year 2025.
Fortress Biotech, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $63.26M +9.7% |
$57.67M -31.8% |
$84.51M +11.6% |
$75.74M +10.1% |
$68.79M +50.9% |
$45.60M +24.5% |
| Net Income | $6.82M +114.8% |
-$46.00M +24.1% |
-$60.64M +30.0% |
-$86.58M -33.8% |
-$64.70M -39.1% |
-$46.53M -16.4% |
| Diluted EPS | -$0.07 +97.4% |
-$2.69 +68.2% |
-$8.47 +47.0% |
-$15.97 -1921.5% |
-$0.79 | — |
| Total Assets | $185.55M +28.7% |
$144.22M -13.9% |
$167.53M -43.1% |
$294.30M -25.8% |
$396.50M +18.9% |
$333.41M +47.3% |
| Cash and Equivalents | $79.38M +38.6% |
$57.26M -29.2% |
$80.93M -54.6% |
$178.27M -41.7% |
$305.74M +31.0% |
$233.35M +70.5% |
| Stockholders Equity | $49.87M +119.3% |
$22.74M +0.9% |
$22.54M -46.0% |
$41.72M -61.6% |
$108.67M +8.3% |
$100.34M +282.8% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$70.22M +36.4% |
-$110.38M +22.5% |
-$142.34M +30.1% |
-$203.56M -8.0% |
-$188.54M -100.0% |
-$94.27M +14.9% |
| Shares Outstanding | 31.36M +12.4% |
27.91M +84.9% |
15.09M +104.9% |
7.37M -92.7% |
101.44M +6.9% |
94.88M +28.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $17.63M | +20.5% | +7.4% |
| Net Income | September 30, 2025 | $5.85M | +145.5% | -62.2% |
| Diluted EPS | September 30, 2025 | $0.11 | +114.5% | -75.6% |
| Total Assets | September 30, 2025 | $181.41M | +42.7% | +13.5% |
| Cash and Equivalents | September 30, 2025 | $86.22M | +46.5% | +15.9% |
| Long-Term Debt | September 30, 2012 | $398.0K | — | — |
| Stockholders Equity | September 30, 2025 | $55.86M | +164.0% | +27.2% |
| R&D Expense | March 31, 2019 | $23.27M | -6.8% | -6.8% |
| Operating Income | September 30, 2025 | -$6.81M | +69.2% | +81.3% |
| Gross Profit | September 30, 2016 | $934.0K | +3636.0% | -51.0% |
| Shares Outstanding | September 30, 2025 | 31.01M | +12.4% | +4.2% |
- Fortress Biotech, Inc. reported Total Revenue of $63.26 million for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +9.7% in Total Revenue compared to the prior fiscal year.
- Fortress Biotech, Inc. reported Net Income of $6.82 million for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +114.8% in Net Income compared to the prior fiscal year.
- Fortress Biotech, Inc. reported Diluted EPS of $0.07 per share (loss) for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +97.4% in Diluted EPS compared to the prior fiscal year.
- Fortress Biotech, Inc. reported Total Assets of $185.55 million for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +28.7% in Total Assets compared to the prior fiscal year.
- Fortress Biotech, Inc. reported Cash and Equivalents of $79.38 million for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +38.6% in Cash and Equivalents compared to the prior fiscal year.
- Fortress Biotech, Inc. reported Stockholders Equity of $49.87 million for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +119.3% in Stockholders Equity compared to the prior fiscal year.
- Fortress Biotech, Inc. reported R&D Expense of $83.33 million for fiscal year 2018.
- Fortress Biotech, Inc. showed an increase of +72.5% in R&D Expense compared to the prior fiscal year.
- Fortress Biotech, Inc. reported Operating Income of -$70.22 million for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +36.4% in Operating Income compared to the prior fiscal year.
- Fortress Biotech, Inc. reported Shares Outstanding of 31.36 million shares for fiscal year 2025.
- Fortress Biotech, Inc. showed an increase of +12.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: